

1. Kimura N, Takahashi Y, Shigematsu H, Imai K, Ikeda H, Otani H, Takayama R, Mogami Y, Kimura N, Baba K, Matsuda K, Tottori T, Usui N, Kondou S, Inoue Y. Risk factors of cognitive impairment in pediatric epilepsy patients with focal cortical dysplasia. *Brain Dev* 2019; 41: 77-84.
2. Yamamoto Y, Takahashi Y, Imai K, Ohta A, Kagawa Y, Inoue Y. Prevalence and risk factors for hyponatremia in adult epilepsy patients: Large-scale cross-sectional cohort study. *Seizure* 2019; 73: 26-30.
3. Yamamoto Y, Takahashi Y, Ikeda H, Imai K, Kagawa Y, Inoue Y. Impact of CYP2C19 phenotypes on clinical efficacy of stiripentol in Japanese patients with Dravet syndrome. *Ther Drug Monit* 2019 Jul 15.
4. Yanagishita T, Yamamoto-Shimajima K, Nakano S, Sasaki T, Shigematsu H, Imai K, Yamamoto T. Phenotypic features of 1q41q42 microdeletion including WDR26 and FBXO28 are clinically recognizable: The first case from Japan. *Brain Dev* 2019; 41: 452-455.
5. Yoshitomi S, Ishii A, Koshimizu E, Saitsu H, Imai K, Kato M, Nakashima M, Matsumoto N, Miyatake S, Hirose S, Fujita T, Takahashi Y, Inoue Y. Different types of suppression-burst patterns in patients with epilepsy of infancy with migrating focal seizures (EIMFS). *Seizure* 2019; 65: 118-123.
6. Yoshitomi S, Takahashi Y, Yamaguchi T, Oboshi T, Horino A, Otani H, Ikeda H, Imai K, Shigematsu H, Inoue Y, Okanishi T, Nakashima M, Matsumoto, Yoshimoto J, Ishii A, Hirose S. Quinidine therapy and therapeutic drug monitoring in four patients with KCNT1 mutation. *Epileptic Disord* 2019; 21: 48-54.
7. Yoshitomi S, Takahashi Y, Yamaguchi T, Imai K, Ishii A, Hirose S, Inoue Y, Efficacy and tolerability of perampamil in pediatric patients with Dravet syndrome. *Epilepsy Res* 2019; 154: 34-38.
8. Takata A, Nakashima M, Saitsu H, Mizuguchi T, Mitsuhashi S, Takahashi Y, Okamoto N, Osaka H, Nakamura K, Tohyama J, Haginoya K, Takeshita S, Kuki I, Okanishi T, Goto T, Sasaki M, Sakai Y, Miyake N, Miyatake S, Tsuchida N, Iwama K, Minase G, Sekiguchi F, Fujita A, Imagawa E, Koshimizu E, Uchiyama Y, Hamanaka K, Ohba C, Itai T, Aoi H, Saida K, Sakaguchi T, Den K, Takahashi R, Ikeda H, Yamaguchi T, Tsukamoto K, Yoshitomi S, Oboshi T, Imai K, Kimizu T, Kobayashi Y, Kubota M, Kashii H, Baba S, Iai M, Kira R, Hara M, Ohta M, Miyata Y, Miyata R, Takanashi JI, Matsui J, Yokochi K, Shimono M, Amamoto M, Takayama R, Hirabayashi S, Aiba K, Matsumoto H, Nabatame S, Shiihara T, Kato M, Matsumoto N. Comprehensive analysis of coding variants highlights

- genetic complexity in developmental and epileptic encephalopathy. *Nat Commun* 2019; 10: 2506.
9. Yamamoto T, Imaizumi T, Yamamoto-Shimajima K, Lu Y, Yanagishita T, Shimada S, Chong PF, Kira R, Ueda R, Ishiyama A, Takeshita E, Momosaki K, Ozasa S, Akiyama T, Kobayashi K, Oomatsu H, Kitahara H, Yamaguchi T, Imai K, Kurahashi H, Okumura A, Oguni H, Seto T, Okamoto N. Genomic backgrounds of Japanese patients with undiagnosed neurodevelopmental disorders. *Brain Dev* 2019; 41: 776-782.
 10. Yamamoto T, Shimajima K, Ueda Y, Imai K, Takahashi Y, Imagawa E, Miyake N, Matsumoto N. Independent occurrence of de novo HSPD1 and HIP1 variants in male brothers with different neurological disorders – leukodystrophy and autism. *Hum Genome Var* 2018; 5: 18.
 11. Kumada T, Imai K, Takahashi Y, Nabatame S, Oguni H. Ketogenic diet using a Japanese ketogenic milk for patients with epilepsy: A multi-institutional study. *Brain Dev* 2018; 40: 188-195.
 12. Takayama R, Imai K, Ikeda H, Baba K, Usui N, Takahashi Y, Inoue Y. Successful hemispherotomy in two refractory epilepsy patients with cerebral hemiatrophy and contralateral EEG abnormalities. *Brain Dev* 2018; 40: 601-606.
 13. Kimizu T, Takahashi Y, Oboshi T, Horino A, Omatsu H, Koike T, Yoshitomi S, Yamaguchi T, Otani H, Ikeda H, Imai K, Shigematsu H, Inoue Y. Chronic dysfunction of blood-brain barrier in patients with post-encephalitic/encephalopathic epilepsy. *Seizure* 2018; 63: 85-90.
 14. Yamamoto Y, Usui N, Nishida T, Mori M, Takahashi Y, Imai K, Kagawa Y, Inoue Y. Influence of renal function on pharmacokinetics of antiepileptic drugs metabolized by CYP3A4 in a patient with renal impairment. *Ther Drug Monit* 2018; 40: 144-147.
 15. Yamamoto Y, Takahashi Y, Horino A, Usui N, Nishida T, Imai K, Kagawa Y, Inoue Y. Influence of Inflammation on the Pharmacokinetics of Peramppanel. *Ther Drug Monit* 2018; 40: 725-729.
 16. Ikeda H, Imai K, Ikeda H, Matsuda K, Takahashi Y, Inoue Y. Ictal single photon emission computed tomographic study of myoclonic absence seizure. *Brain Dev* 2018; 40: 126-129.
1. 高橋幸利、今井克美、山口解冬、大星大観、池田浩子、吉富晋作、木水友一、小池敬義、堀野朝子、大松泰生. ケトンフォーミュラの難治てんかん症例における

治療効果. 脳と発達 2018 ; 50 : 44-49.

2. 今井克美. ACTH療法、食事療法 - ケトン食などのてんかん食. Pharma Medica. 2018 ; 36 : 49-53.
3. 今井克美. Q25 食事療法はどのように行われますか? 谷口豪、西田拓司、廣實真弓編「てんかん支援 Q&Aーリハビリ・生活支援の実践」p.66-67、医歯薬出版株式会社、東京、2018年6月1日発行.